Harpoon: Harpoon Therapeutics : June 3, 2024

(marketscreener.com) June 3, 2024 8:00 am ET At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients ...https://www.marketscreener.com/quote/stock/HARPOON-THERAPEUTICS-INC-54488892/news/Harpoon-Therapeutics-June-3-2024-46887705/?utm_medium=RSS&utm_content=20240603